Supplemental Fig. 1. Kaplan-Meier estimates of overall survival according to treatment in miR-21 positive patients (A) compared with miR-21 negative patients (B), in miR-29b positive patients (C) compared with miR-29b negative patients (D), in miR-34a positive patients (E) compared with miR-34a negative patients (F), in miR-34b positive patients (G) compared with miR-34b negative patients (H), in miR-34c positive patients (I) compared with miR-34c negative patients (J), in miR-155 positive patients (K) compared with miR-155 negative patients (L), in Let-7a positive patients (M) compared with Let-7a negative patients (N)
Overall survival in miR-21 negative group by treatment

At risk

Overall survival in miR-21 positive group by treatment

At risk

Overall survival in miR-29b negative group by treatment

At risk

Overall survival in miR-29b positive group by treatment

At risk

Overall survival in miR-34a negative group by treatment

At risk

Overall survival in miR-34a positive group by treatment

At risk

Overall survival in miR-34b negative group by treatment

At risk

Overall survival in miR-34b positive group by treatment

At risk
Overall survival in miR-34c negative group by treatment

- control (88 deaths)
- chemotherapy (106 deaths)

At risk: 146 120 99 83 70 60 47 37 36 24

Overall survival in miR-34c positive group by treatment

- control (95 deaths)
- chemotherapy (98 deaths)

At risk: 152 126 101 88 79 66 48 33 20 9

Overall survival in miR-155 negative group by treatment

- control (98 deaths)
- chemotherapy (111 deaths)

At risk: 161 131 110 92 78 50 39 24

Overall survival in miR-155 positive group by treatment

- control (90 deaths)
- chemotherapy (100 deaths)

At risk: 147 125 98 88 78 52 36 24

Overall survival in Let-7a negative group by treatment

- control (101 deaths)
- chemotherapy (111 deaths)

At risk: 160 129 103 90 74 61 49 34 25

Overall survival in Let-7a positive group by treatment

- control (89 deaths)
- chemotherapy (100 deaths)

At risk: 149 127 105 89 81 71 52 40 23